These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36288390)

  • 1. Estimating treatment costs for uncomplicated diabetes at a hospital serving refugees in Kenya.
    Masis L; Kanya L; Kiogora J; Kiapi L; Tulloch C; Alani AH
    PLoS One; 2022; 17(10):e0276702. PubMed ID: 36288390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivering a primary-level non-communicable disease programme for Syrian refugees and the host population in Jordan: a descriptive costing study.
    Ansbro É; Garry S; Karir V; Reddy A; Jobanputra K; Fardous T; Sadique Z
    Health Policy Plan; 2020 Oct; 35(8):931-940. PubMed ID: 32621490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening.
    Thomas RL; Winfield TG; Prettyjohns M; Dunstan FD; Cheung WY; Anderson PM; Peter R; Luzio SD; Owens DR
    Eur J Health Econ; 2020 Sep; 21(7):993-1002. PubMed ID: 32385543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
    J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pattern, knowledge and practices of HbA1C testing among diabetic patients in a Kenyan tertiary referral hospital.
    Matheka DM; Kilonzo JM; Munguti CM; Mwangi PW
    Global Health; 2013 Nov; 9():55. PubMed ID: 24192011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
    Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
    Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of Disease in Refugee Patients with Diabetes on the Island of Lesvos-The Experience of a Frontline General Hospital.
    Bountouvis N; Koumpa E; Skoutarioti N; Kladitis D; Exadaktylos AK; Anitsakis C
    Int J Environ Res Public Health; 2024 Jun; 21(7):. PubMed ID: 39063405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of managing Type 2 diabetes mellitus: Analysis from a Teaching Hospital in Malaysia.
    Ismail A; Suddin LS; Sulong S; Ahmed Z; Kamaruddin NA; Sukor N
    Indian J Public Health; 2017; 61(4):243-247. PubMed ID: 29219128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study.
    Giorda CB; Rossi MC; Ozzello O; Gentile S; Aglialoro A; Chiambretti A; Baccetti F; Gentile FM; Romeo F; Lucisano G; Nicolucci A;
    Nutr Metab Cardiovasc Dis; 2017 Mar; 27(3):209-216. PubMed ID: 28017523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
    Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
    Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
    Salas M; Ward A; Caro J
    Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of an intelligent chronic disease management system on patients with type 2 diabetes mellitus in a Beijing community.
    Xue-Juan W; Hao W; Cai-Ying G; Xin-Ying L; Hong-Yan J; Li W; Xiao-Ling G; Wan-Ying L; Wen-Juan G; Wan-Nian L
    BMC Health Serv Res; 2018 Oct; 18(1):821. PubMed ID: 30373577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of diabetes: comparison of disease-attributable and matched cohort cost estimation methods.
    Tunceli O; Wade R; Gu T; Bouchard JR; Aagren M; Luo W
    Curr Med Res Opin; 2010 Aug; 26(8):1827-34. PubMed ID: 20491613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study.
    Zaccardi F; Rocca B; Rizzi A; Ciminello A; Teofili L; Ghirlanda G; De Stefano V; Pitocco D
    Nutr Metab Cardiovasc Dis; 2017 Oct; 27(10):902-909. PubMed ID: 28838851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States.
    Aagren M; Luo W
    J Med Econ; 2011; 14(1):108-14. PubMed ID: 21241161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation.
    Stedman M; Lunt M; Davies M; Livingston M; Duff C; Fryer A; Anderson SG; Gadsby R; Gibson M; Rayman G; Heald A
    BMJ Open; 2020 May; 10(5):e033231. PubMed ID: 32376746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are outpatient costs for hypertension and diabetes care affordable? Evidence from Western Kenya.
    Kishindo M; Kamano J; Mwangi A; Andale T; Mwaura GW; Limo O; Too K; Mugo R; Maree E; Aruasa W
    Afr J Prim Health Care Fam Med; 2023 Sep; 15(1):e1-e9. PubMed ID: 37916717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.
    Bron M; Guerin A; Latremouille-Viau D; Ionescu-Ittu R; Viswanathan P; Lopez C; Wu EQ
    J Med Econ; 2014 Sep; 17(9):646-57. PubMed ID: 24959693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.